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Background. Non-medical use of prescription opioids represents a national public health concern of growing
importance. Mood and anxiety disorders are highly associated with non-medical prescription opioid use. The authors
examined longitudinal associations between non-medical prescription opioid use and opioid disorder due to non-
medical opioid use and mood/anxiety disorders in a national sample, examining evidence for precipitation, self-
medication and general shared vulnerability as pathways between disorders.
Method. Data were drawn from face-to-face surveys of 34 653 adult participants in waves 1 and 2 of the National
Epidemiologic Survey on Alcohol and Related Conditions. Logistic regression models explored the temporal
sequence and evidence for the hypothesized pathways.
Results. Baseline lifetime non-medical prescription opioid use was associated with incidence of any mood disorder,
major depressive disorder (MDD), bipolar disorder, any anxiety disorder and generalized anxiety disorder (GAD in
wave 2, adjusted for baseline demographics, other substance use, and co-morbid mood/anxiety disorders). Lifetime
opioid disorder was not associated with any incident mood/anxiety disorders. All baseline lifetime mood disorders
and GAD were associated with incident non-medical prescription opioid use at follow-up, adjusted for
demographics, co-morbid mood/anxiety disorders, and other substance use. Baseline lifetime mood disorders, MDD,
dysthymia and panic disorder were associated with incident opioid disorder due to non-medical prescription opioid
use at follow-up, adjusted for the same covariates.
Conclusions. These results suggest that precipitation, self-medication as well as shared vulnerability are all viable
pathways between non-medical prescription opioid use and opioid disorder due to non-medical opioid use and
mood/anxiety disorders.
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Introduction
Prescription opioids are effective treatment for chronic
and acute pain (Walwyn et al. 2010) and although most
people use their medicines appropriately, recently, the
non-medical use of prescription opioids has increased
dramatically in the USA and other countries around
the world (Haydon et al. 2005 ; Huang et al. 2006 ;
Kuehn, 2007 ; Blanco et al. 2007 ; Brands et al. 2010 ;
Monheit, 2010). In 2008, past-year use of non-medical
prescription opioids was second only to marijuana as
the most frequently used illegal drugs in the USA ac-
cording to the Substance Abuse and Mental Health
Services Administration (SAMHSA, 2009). Estimates
from wave 1 of the National Epidemiologic Study on
Alcohol and Related Conditions (NESARC) indicate
that approximately 4.1% of the US adult population
met criteria for non-medical prescription opioid use in
their lifetime and that nearly a third of the users met
criteria for a prescription opioid-use disorder in their
lifetime.
Prescription opioids are highly reinforcing and
prolonged use can produce neurological changes
and physiological dependence. Non-medical use of
prescription opioids, which involves use without a
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prescription or in ways not recommended by a doctor
(Huang et al. 2006 ; Blanco et al. 2007), is extremely
dangerous and potentially fatal (Walwyn et al. 2010),
representing a national public health concern of
growing importance.
Non-medical users have an increased risk of de-
veloping a Diagnostic and Statistical Manual of Mental
Disorders, 4th edition (DSM-IV) opioid-use disorder
(Huang et al. 2006 ; SAMHSA, 2010). To design effec-
tive prevention and treatment interventions to reduce
non-medical use-related harm, research is needed
to develop our knowledge of the determinants and
consequences of non-medical prescription opioid use.
Cross-sectionally ascertained samples have shown
that mood and anxiety disorders are strongly as-
sociated with non-medical prescription opioid use and
disorder (Sullivan et al. 2005 ; Huang et al. 2006 ; Becker
et al. 2008 ; Tetrault et al. 2008 ; Grella et al. 2009), and
may be particularly salient to our understanding of
non-medical use. However, the etiological relevance
and clinical implications of this association depend on
the temporal sequence of the onset of these disorders.
If pre-existing psychiatric disorders lead to non-
medical use then prevention interventions focusing on
individuals with mood and anxiety disorders may be
necessary. Furthermore, careful screening and moni-
toring of non-medical use may be required among
individuals with these disorders who are prescribed
opiate medication for pain. If mood and anxiety dis-
orders are a consequence of non-medical prescription
opioid use, then interventions among non-medical
prescription opioid users may require an additional
mood/anxiety disorder prevention or treatment com-
ponent. Causal hypotheses remain largely unex-
plored, as current knowledge of possible mechanisms
of the linkage between mood and anxiety and opioid
use is limited.
The association between mood/anxiety disorders
and non-medical prescription opioid use can arise
in one or more non-mutually exclusive ways: non-
medical prescription opioid use leads to mood/
anxiety disorders (‘precipitation’ hypothesis), mood/
anxiety disorders lead to non-medical prescription
opioid use (‘self-medication ’ hypothesis), and/or a
third factor influences vulnerability to both (‘shared
vulnerability ’). Additionally, these pathways may
be operating in a bi-directional and synergistic way
or only among certain subgroups. For example,
one model (‘precipitation’) suggests that non-medical
prescription opioid use could precipitate (i.e. lead to)
mood and anxiety disorders. Specifically, behavioral
and neural plasticity resulting from heavy drug use
could trigger mood or anxiety disorders (Brady &
Sinha, 2005). This may be particularly evident among
individuals who develop DSM-IV opioid-use disorder
due to non-medical use, since to develop a disorder
their use of prescription opiates may be especially
heavy. In support of this pathway, the DSM-IV in-
cludes diagnoses of substance (including prescription
opioid)-induced mood anxiety disorders (APA, 1994).
Thus in the precipitational model, non-medical pre-
scription opioid use occurs before the onset of mood
and anxiety disorders. In contrast, a second model
(‘self-medication ’) postulates that individuals with
mood and anxiety disorders may use prescription
opioids non-medically in order to temporarily relieve
symptoms of anxiety and depression (Emrich et al.
1982 ; Saitoh et al. 2004). This pathway is grounded in a
long history of basic science research demonstrating
the anxiolytic and antidepressant properties of opioids
(Emrich et al. 1982 ; Weber & Emrich, 1988). As an ex-
tension of this, individuals with substantial pain
may develop mood and anxiety disorders, and then
engage in non-medical use of pain medication to re-
lieve psychiatric symptoms, i.e. mood and anxiety
disorders mediate the association between pain and
non-medical use. In self-medication models, non-
medical prescription opioid use occurs after mood and
anxiety disorders.
A third model (‘shared vulnerability ’), which does
not require sequencing, is an underlying shared vul-
nerability, in which a third factor (e.g. genetic liability,
environmental stressors) influences risk for both drug
use/dependence and psychiatric disorders. This is
supported by behavioral genetic studies (Krueger et al.
2001 ; Young et al. 2002 ; Kendler et al. 2003; Lyons et al.
2008). This model may explain the association between
non-medical prescription opioid use and prescription
opioid disorderwithmood/anxiety disorders if under-
lying genetic factors influence both mood/anxiety
disorders and non-medical prescription opioid use/
prescription opioid disorder.
Previously, using diagnostic information obtained
retrospectively among a large and nationally represen-
tative population based-sample, we found evidence
for the existence of both precipitational and self-
medication models as well as for an underlying shared
vulnerability (Martins et al. 2009a). However, the se-
quence of non-medical prescription opioid use and
mood and anxiety disorders can be better understood
with longitudinal population-based data on incident
and pre-existing use and diagnoses. Schepis & Hakes
(2011) found evidence for the association between
past-year non-medical prescription opioid use and
incident bipolar disorder among NESARC respon-
dents with past psychopathology, as well as between
lifetime non-medical prescription opioid use and in-
cident depressive, bipolar and anxiety disorder among
those with no history of psychopathology. However,
Schepis & Hakes (2011) did not examine the influence
1262 S. S. Martins et al.
of psychopathology on non-medical opioid use and
disorder, or the influence of opioid disorder due to
non-medical use on psychopathology. The present
study was designed to provide novel information on
longitudinal associations between non-medical pre-
scription opioid use and opioid disorder due to non-
medical opioid use with mood/anxiety disorders
using data from the two waves of NESARC data col-
lected approximately 3 years apart. The NESARC is a
large nationally representative epidemiologic study
which includes prospective, reliable and valid infor-
mation on drug use and psychiatric diagnoses, and
therefore represents a unique opportunity to examine
the evidence for the precipitation, self-medication and
general vulnerability models. A precipitational path-
way is supported if non-medical prescription opioid
use and disorders due to this use at baseline predict
incident mood/anxiety disorders at follow-up. A self-
medication pathway is supported if mood/anxiety
disorders at baseline predict incident non-medical
prescription opioid use and disorders due to this use
at follow-up. A general vulnerability model is sup-
ported if evidence is present for both pathways. Our
aim is not to tease apart the pathways; rather, we
provide the first demonstration of longitudinal inci-
dence data in a population-based sample and provide




The NESARC is a longitudinal survey with its first
wave of interviews fielded in 2001–2002 and second
wave in 2004–2005. The target population was the
civilian non-institutionalized population residing in
households and group quarters, aged 18 years and
older. Blacks, Hispanics and young adults (aged 18–24
years) were oversampled, with data adjusted for
oversampling, household- and person-level non-
response. The weighted data were then adjusted to
represent the US civilian population based on the 2000
Census. Interviews were conducted face-to-face by
extensively trained interviewers of the US Bureau of
the Census. In 2001–2002 (wave 1 of the study), 43 093
individuals were assessed for a lifetime history of
psychiatric disorders as well as other information
(Grant et al. 2004b). For wave 2 (Hatzenbuehler et al.
2008), conducted in 2004–2005, interviewers re-
interviewed all possible eligible respondents from
wave 1. Excluding respondents ineligible for the wave
2 interview because they were deceased (n=1403),
deported, mentally or physically impaired (n=781) or
on active duty in the armed forces throughout the
follow-up period (n=950), the wave 2 response rate
was 86.7%, with a cumulative response rate over the
two surveys of 70.2%. Data were reweighted at wave 2
to account for differential loss to follow-up and to be
representative of the target population. This analysis
includes the 34 653 respondents who completed inter-
views at waves 1 and 2. The demographic character-
istics of the eligible sample are provided in Table 1. All
potential NESARC respondents were informed in
writing about the nature of the survey, the statistical
uses of the survey data, the voluntary aspect of their
participation, and the federal laws that provide for the
confidentiality of identifiable survey information.
Respondents who gave consent were then inter-
viewed. The research protocol, including informed
consent procedures, was approved by the Census
Bureau’s review board and the US Office of
Management and Budget.
Measures
The Alcohol Use Disorder and Associated Disabilities
Interview Schedule (AUDADIS)-IV (Grant et al. 2003),
a structured diagnostic interview, was administered to
NESARC participants using computer-assisted soft-
ware with built-in skip, logic and consistency checks.
This instrument was specifically designed for experi-
enced lay interviewers and was developed to advance
measurement of substance use and mental disorders
in large-scale surveys.
Non-medical prescription opioid use and opioid disorder
due to non-medical use
Non-medical use of prescription opioids was defined
to respondents as using a prescription opioid : ‘with-
out a prescription, in greater amounts, more often, or
longer than prescribed, or for a reason other than a
doctor said you should use them’. After the initial
probe item, the respondent was given an extensive list
of examples of prescription opioids and asked if she/
he used any of the prescription opioids on the list or
similar drugs ‘non-medically ’. If the response was
positive, the respondent was asked to specify which
prescription opioid she/he has used, when she/he
had used it (lifetime, past year, since last interview) as
well as asked about lifetime, past year and since last
interview frequency of use (for the purpose of this
study those that had used prescription opioids non-
medically 12 or more times in their lifetime were
classified as heavy users), and then the interviewer
recorded the response. Over 30 symptom items are
used by the AUDADIS to operationalize DSM-IV cri-
teria to assess lifetime abuse and dependence accord-
ing to DSM-IV criteria (Saitoh et al. 2004). k Values for
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Table 1. Incident non-medical prescription opioid use, incident opioid disorder due to non-medical prescription opioid use, any incident mood disorder and any incident anxiety disorder in the overall








































Sex Male (n=14 564) 2.37 (0.16) 1.0 Ref. 0.73 (0.10) 1.0 Ref. 5.43 (0.25) 1.0 Ref. 4.86 (0.22) 1.0 Ref.
Female (n=20 089) 2.01 (0.12) 0.8 (0.7–1.0)* 0.53 (0.01) 0.7 (0.5–1.0) 8.61 (0.33) 1.6 (1.5–1.8)*** 8.67 (0.34) 1.9 (0.6–2.1)***
Age at baseline,
years
18–29 (n=6719) 3.89 (0.32) 1.00 Ref. 1.33 (0.21) 1.0 Ref. 10.16 (0.55) 1.0 Ref. 8.69 (0.46) 1.0 Ref.
30–44 (n=11 013) 2.21 (0.17) 0.6 (0.5–0.7)*** 0.55 (0.01) 0.4 (0.3–0.6)*** 7.72 (0.36) 0.7 (0.6–0.9)*** 7.50 (0.34) 0.9 (0.7–0.0)*
45–64 (n=10 917) 1.64 (0.16) 0.4 (0.3–0.5)*** 0.43 (0.01) 0.3 (0.2–0.6)*** 6.02 (0.36) 0.6 (0.5–0.7)*** 6.50 (0.36) 0.7 (0.6–0.9)***
65+ (n=6004) 0.89 (0.14) 0.2 (0.2–0.3)*** 0.18 (0.01) 0.1 (0.1–0.3)*** 3.81 (0.31) 0.4 (0.3–0.4)*** 3.38 (0.31) 0.4 (0.3–0.5)***
Race/ethnicity White (n=20 174) 2.33 (0.13) 1.0 Ref. 0.67 (0.01) 1.0 Ref. 6.42 (0.24) 1.0 Ref. 6.83 (0.24) 1.0 Ref.
African-American (n=6577) 1.94 (0.21) 0.8 (0.7–1.1) 0.43 (0.12) 0.6 (0.4–1.1) 8.34 (0.46) 1.3 (1.1–1.5)*** 7.10 (0.45) 1.0 (0.9–0.2)
Native-American (n=580) 1.76 (0.51) 0.8 (0.4–1.3) 0.51 (0.30) 0.8 (0.2–2.6) 10.87 (1.72) 1.8 (1.2–2.6)*** 7.09 (1.37) 1.0 (0.7–0.6)
Asian (n=966) 1.41 (0.54) 0.6 (0.3–1.3) 0.46 (0.42) 0.7 (0.1–4.4) 6.23 (1.23) 1.0 (0.6–1.5) 5.09 (0.99) 0.7 (0.5–0.1)
Hispanic (n=6356) 1.88 (0.24) 0.8 (0.6–1.1) 0.58 (0.15) 0.9 (0.5–1.5) 8.71 (0.55) 1.4 (1.1–1.6)*** 6.46 (0.54) 0.9 (0.8–0.1)
Annual family
income, $
0 to 19 999 (n=9366) 2.39 (0.24) 1.0 Ref. 0.69 (0.14) 1.0 Ref. 8.87 (0.43) 1.0 Ref. 7.17 (0.42) 1.0 Ref.
20 000 to 34 999 (n=7381) 1.97 (0.19) 0.8 (0.6–1.1) 0.53 (0.01) 0.8 (0.4–1.3) 7.11 (0.41) 0.8 (0.7–0.9)* 7.29 (0.45) 1.0 (0.8–0.2)
35 000 to 69 999 (n=10 904) 2.27 (0.18) 0.9 (0.7–1.2) 0.70 (0.11) 1.0 (0.6–1.7) 6.55 (0.36) 0.7 (0.6–0.8)*** 6.13 (0.34) 0.8 (0.7–0.0)*
70 000+ (n=7002) 2.24 (0.18) 0.9 (0.7–1.1) 0.54 (0.12) 0.8 (0.4–1.5) 5.94 (0.41) 0.6 (0.5–0.8)*** 6.75 (0.42) 0.9 (0.8–0.1)
Employment
status
Unemployed (n=12 246) 2.07 (0.19) 1.0 Ref. 0.66 (0.12) 1.0 Ref. 7.17 (0.32) 1.0 Ref. 6.74 (0.31) 1.0 Ref.
Employed (n=22 407) 2.24 (0.12) 0.9 (0.8–1.1) 0.60 (0.01) 1.1 (0.7–1.7) 6.92 (0.27) 1.0 (0.9–1.2) 6.75 (0.27) 1.0 (0.9–0.1)
Marital status Married (n=18 413) 1.66 (0.01) 1.0 Ref. 0.44 (0.01) 1.0 Ref. 6.11 (0.25) 1.0 Ref. 6.08 (0.25) 1.0 Ref.
Previously married
(n=8564)
2.09 (0.20) 1.3 (1.0–1.6)* 0.64 (0.12) 1.4 (0.9–2.3) 6.75 (0.37) 1.1 (1.0–1.3) 7.09 (0.44) 1.2 (0.0–0.4)*
Never married (n=7676) 3.87 (0.33) 2.4 (2.0–2.9)*** 1.17 (0.20) 2.7 (1.7–4.1)*** 10.11 (0.51) 1.7 (1.5–2.0)*** 8.50 (0.50) 1.4 (0.2–0.7)***
NESARC, National Epidemiologic Study on Alcohol and Related Conditions ; S.E., standard error ; OR, odds ratio ; CI, confidence interval ; Ref., reference.
a Any mood disorder includes DSM-IV primary major depressive disorder, bipolar I disorder, bipolar disorder and dysthymia.
b Any anxiety disorder includes primary panic disorder, social anxiety disorder and specific phobia and generalized anxiety disorder.
c Crude (unadjusted) OR.










the AUDADIS-IV diagnosis of lifetime non-medical
prescription opioid use and disorder due to non-
medical prescription opioid use in general population
and clinical settings range from 0.59 for lifetime de-
pendence to 0.66 for lifetime use (Grant et al. 1995 ;
Hasin et al. 1997), indicating the test–retest reliability
to be good to fair (Fleiss, 1981; Byrt, 1996 ; Szklo &
Javier-Nieto, 2004). It is important to note that wave 2
of the NESARC combines prescription opioids with
cyclo-oxygenase-2 (Cox-2) inhibitors (which have no
abuse potential) in a single question about the non-
medical use of prescription pain medications, which
could have partially inflated the incidence rate of
prescription opioid use (but not disorder) in our study
(Boyd &McCabe, 2009). Due to this problem in wave 2
assessment we conducted sensitivity analyses that re-
moved all incident non-medical users who did not
endorse at least one non-medical opioid-use disorder
question in wave 2 (the total no. of incident non-
medical prescription opioid users decreased to 553).
Odds ratios (ORs) in the sensitivity analyses were very
similar to those in which we included all incident non-
medical prescription opioid users (n=728), suggesting
minimal/no bias due to the inclusion of Cox-2 inhibi-
tor use in the list of non-medical prescription opioids
in wave 2 of the NESARC (data not shown, available
upon request).
Mood and anxiety disorders
Mood disorders included DSM-IV primary major de-
pressive disorder (MDD), bipolar disorder, bipolar I
disorder and dysthymia. Anxiety disorders included
DSM-IV primary panic disorder, social anxiety dis-
order and specific phobia and generalized anxiety
disorder (GAD). Diagnostic methods used in the
AUDADIS-IV are described in detail elsewhere (Grant
et al. 2004b, 2005 ; Hasin et al. 2005). In DSM-IV, ‘pri-
mary’ excludes substance-induced disorders or those
due to medical conditions ; specific AUDADIS ques-
tions about the chronological relationship between
intoxication or withdrawal and the full psychiatric
syndrome implement DSM-IV criteria differentiating
primary from substance-induced disorders. MDD
diagnoses also ruled out bereavement. Test–retest re-
liability for AUDADIS-IVmood and anxiety diagnoses
in general population and clinical settings was good
to fair with k agreement statistics ranging from 0.42
for social anxiety disorder to 0.64 for MDD (Hasin et al.
1997 ; Canino et al. 1999 ; Grant et al. 2003). For the pur-
pose of this study, besides the specific disorder vari-
ables, we created a variable that combined all DSM-IV
mood disorders that a respondent endorsed as well as
a variable that combined all DSM-IV anxiety disorders
that a respondent endorsed.
Other substance use, alcohol disorder and other drug-use
disorder
The AUDADIS-IV assessed lifetime use of alcohol and
other illegal drugs at wave 1 of the NESARC (e.g.
marijuana, cocaine, heroin, hallucinogens, inhalants,
and non-medical use of stimulants, sedatives and
tranquilizers) with similar sets of questions as those
described for non-medical prescription opioid use. For
the purpose of this study we used data on alcohol and
any other illegal drug use that occurred prior to base-
line as two separate control variables (one for alcohol,
one for all other illegal drugs) in the models in which
non-medical use was the predictor of interest. Simi-
larly, the AUDADIS-IV included extensive questions
to operationalize DSM-IV criteria to assess lifetime
alcohol-use disorders and other drug-use disorders
(Saitoh et al. 2004). For the purpose of this study we
used baseline data on alcohol and other drug-use dis-
orders into two separate control variables for the
models in which opioid disorder due to non-medical
use was the predictor of interest. AUDADIS-IV criteria
and diagnoses for alcohol- and drug-use disorders
have fair to excellent reliabilities (k values 0.53–0.84)
(Grant et al. 1995; Hasin et al. 1997).
Demographic correlates
We examined the following potential correlates of
non-medical prescription opioid use and prescription
opioid disorder due to non-medical opioid use for in-
clusion as control variables : sex, age, race/ethnicity,
family income, employment status and marital status
(see Table 1).
Incidence
Incidence was defined as new cases of non-medical
opioid use or disorder due to non-medical opioid use
among those with no history at wave 1 or new cases of
psychiatric disorder among those with no history at
wave 1 in the period comprised between NESARC
wave 1 and wave 2 interviews (since last interview).
Statistical analysis
To examine the precipitational pathway, two sets of
nested logistic regression analyses examined whether
lifetime non-medical prescription opioid use and dis-
orders due to this use predict incident mood/anxiety
disorders (any mood or anxiety disorder and specific
mood/anxiety disorders) at follow-up. First, demo-
graphics were included in the models as covariates.
Second, to test whether these associations persisted
independently of other substance-use and co-morbid
mood/anxiety disorders, we controlled for baseline
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substance-use variables (with indicator variables
representing other substance use) and baseline co-
morbid mood/anxiety disorders (a binary variable
representing baseline co-morbid mood/anxiety dis-
orders, n varies by model, available upon request). In
the models in which non-medical use was the predic-
tor of interest, substance-use covariates included
baseline lifetime alcohol (n=28 482, 83.4% of the
baseline respondents) and other drug use (marijuana,
cocaine, hallucinogens, inhalants, heroin, non-medical
stimulants, non-medical sedatives and non-medical
tranquilizers : n=7497, 22.5% of the baseline respon-
dents). In the models in which the predictor of interest
was disorders due to non-medical use we included
baseline lifetime alcohol disorder (n=9937, 30.4% of
the baseline respondents) and other drug-use disorder
(n=3332, 10.1% of the baseline respondents) as co-
variates.
Similarly, two sets of nested logistic regression
models were generated to address the self-medication
pathway and determine whether mood/anxiety dis-
orders at baseline predict incident non-medical pre-
scription opioid use and disorders due to this use
at follow-up. First, we controlled for demographics.
Second, to test whether these associations persisted
independent of co-morbid mood/anxiety disorders, a
binary variable representing all other baseline lifetime
mood/anxiety disorders (n varies by model, available
upon request) was included. In addition, these models
also controlled for baseline other substance-use dis-
orders variables (described in detail in the former
paragraph). Stata release 10.0 survey commands were
used in all analyses to account for sample weighting
and the complex survey design (StataCorp LP, USA).
Results
Incidence at wave 2 (Table 1)
Among the sample of 34 653, there were 728 (2.3%)
incident non-medical prescription opioid users and
191 (0.6%) subjects who met criteria for opioid dis-
order (abuse and/or dependence) due to non-medical
prescription opioid use in wave 2 of the NESARC.
Males, those in the younger age group, and those
never married or no longer married were more likely
to initiate non-medical opioid use in the interval be-
tween wave 1 and wave 2. Respondents in the younger
age group and those never married were more likely
to meet criteria for an opioid disorder due to non-
medical use in wave 2.
Additionally, there were 2032 (7.0%) respondents
with incident mood disorders and 2003 (6.7%) re-
spondents with incident anxiety disorders in wave 2
of the NESARC. Incident mood disorders at wave 2
were more likely to develop among females, those
in the younger age group, African-Americans, Native
Americans and Hispanics versus Whites, those
with lower family income and those never married.
Females, those in the younger age group, and those
never married or no longer married were also more
likely to have incident anxiety disorders at wave 2.
The precipitational pathway: does non-medical use
precede mood/anxiety disorders? (Table 2)
Non-medical prescription opioid use
Baseline lifetime non-medical prescription opioid
use was associated with the incidence of any mood
disorder, MDD, bipolar disorder, and all anxiety dis-
orders (any and specific), at follow-up in the models
adjusted for demographics as well as in the models
further adjusted for baseline lifetime other substance
use, and baseline co-morbid lifetime mood/anxiety
disorders (unadjusted models yielding similar results
are available upon request). We ran sensitivity ana-
lyses to examine the precipitational pathway focusing
on non-medical prescription opioid users that can be
considered as heavy prescription opioid users (used
prescription opioids non-medically at least 12 times
in their lifetime) and findings were very similar to the
ones obtained when we included all lifetime non-
medical prescription opioid users.
Non-medical opioid disorder due to non-medical use
Baseline lifetime non-medical opioid disorder due to
non-medical prescription opioid use was associated
with any mood disorder, any anxiety disorder, as well
as with several incident mood disorders and anxiety
disorders at follow-up when adjusted for demo-
graphics only. In the models further adjusted for base-
line lifetime alcohol disorder and drug disorder, and
baseline co-morbid lifetime mood/anxiety disorders,
the associations were attenuated and none remained
significantly associated with opioid disorder at
follow-up.
The self-medication pathway: do mood/anxiety
disorders precede non-medical use? (Table 3)
Non-medical prescription opioid use
Almost all baseline lifetime mood/anxiety disorders
(any and specific) were associated with incident
non-medical prescription opioid use at follow-up in
models adjusted for demographics. In the models
further adjusted for other co-morbid baseline mood/
anxiety disorders, and baseline substance use, all
mood disorders (any and specific) and GAD [adjusted
odds ratio (aOR) 1.5, 95% confidence interval (CI)
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Table 2. Assessing the precipitational pathway : baseline lifetime non-medical prescription opioid use and abuse/dependence secondary non-medical use in NESARC wave 1 preceding incident mood/
anxiety disorders in NESARC wave 2
Incident (wave 2) mood and anxiety disordersc
Baseline (wave 1) non-medical prescription opioid-use predictors
Lifetime non-medical prescription
opioid use (n=1499)a controlling for
Lifetime abuse/dependence due to non-medical










disorders ORf (95% CI)
Incident mood disorders
Any mood disorder (n=2032) 2.1 (1.6–2.8)*** 1.8 (1.4–2.3)*** 2.0 (1.3–3.1)** 1.5 (0.9–2.5)
Major depressive disorder (n=1668) 1.7 (1.3–2.2)*** 1.4 (1.1–1.9)* 2.1 (1.3–3.3)** 1.6 (1.0–2.6)
Dysthymia (n=351) 1.4 (0.9–2.4) 1.0 (0.6–1.7) 2.8 (1.3–6.0)** 2.2 (1.0–5.0)
Bipolar I disorder (n=182) 1.7 (0.8–3.6) 1.7 (0.8–3.6) 1.7 (0.5–5.9) 1.9 (0.5–6.9)
Bipolar disorder (n=261) 2.0 (1.1–3.6)* 2.0 (1.1–3.7)* 2.5 (1.0–5.9) 2.6 (1.0–6.8)
Incident anxiety disorders
Any anxiety disorder (n=2003) 1.7 (1.3–2.1)*** 1.4 (1.1–1.8)* 2.0 (1.4–3.0)* 1.6 (1.0–2.4)
Panic disorder (n=647) 1.6 (1.1–2.4)* 1.3 (0.9–2.0) 2.3 (1.2–4.1)** 1.8 (0.9–3.4)
Social anxiety disorder (n=560) 1.7 (1.1–2.5)** 1.1 (0.7–1.7) 1.8 (1.0–3.3) 1.2 (0.6–2.4)
Specific phobia (n=807) 1.5 (1.1–2.2)* 1.4 (1.0–2.0) 1.6 (0.9–2.9) 1.4 (0.8–2.8)
Generalized anxiety disorder (n=1123) 2.1 (1.6–2.8)*** 1.5 (1.1–2.1)** 2.5 (1.6–3.9)*** 1.6 (1.0–2.5)
NESARC, National Epidemiologic Study on Alcohol and Related Conditions ; OR, odds ratio ; CI, confidence interval.
a Reference is absence of lifetime non-medical prescription opioid use at baseline (wave 1).
b Reference is absence of lifetime abuse or dependence secondary to non-medical prescription opioid use at baseline (wave 1).
c In all analyses those with former mood/anxiety disorders were excluded (e.g. to investigate the association between baseline non-medical opioid use and incident major depressive
disorder all respondents with major depressive disorder at baseline were excluded).
d Adjusted for baseline demographics (sex, age, race, and baseline family income, marital status, and employment status).
e Adjusted for baseline demographics, other substance use (alcohol, marijuana, cocaine, hallucinogens, inhalants, heroin, non-medical stimulant, sedative and tranquilizer use),
co-morbid mood/anxiety disorders.
f Adjusted for baseline demographics and other substance-use disorders (alcohol, marijuana, cocaine, hallucinogens, inhalants, heroin, non-medical stimulant, sedative and tranquilizer
use), co-morbid mood/anxiety disorders.















Table 3. Assessing the self-medication pathway : baseline lifetime mood/anxiety disorders in NESARC wave 1 preceding non-medical prescription opioid use and abuse/dependence secondary non-
medical use in NESARC wave 2
Baseline (wave 1) mood and anxiety
disorder predictorsc
Incident (wave 2) non-medical prescription opioid use variables
Incident non-medical prescription
opioid use (n=728)a controlling for
Incident abuse/dependence secondary










substance-use disorders ORe (95% CI)
Lifetime mood disorders
Any mood disorder (n=7082) 1.9 (1.6–2.3)*** 1.6 (1.3–2.0)*** 2.8 (2.0–3.9)*** 2.1 (1.5–3.0)***
Major depressive disorder (n=6004) 1.9 (1.5–2.3)*** 1.5 (1.2–2.8)** 2.6 (1.8–3.6)*** 1.7 (1.2–2.5)**
Dysthymia (n=1577) 2.2 (1.6–3.0)*** 1.6 (1.1–2.3)* 3.6 (2.1–6.4)*** 2.2 (1.1–4.2)*
Bipolar I disorder (n=791) 2.3 (1.5–3.4)*** 1.7 (1.1–2.6)* 1.8 (0.9–3.6) 1.1 (0.5–2.3)
Bipolar disorder (n=1219) 2.5 (1.8–3.6)*** 2.0 (1.4–2.8)*** 2.2 (1.3–3.8)** 1.4 (0.7–2.5)
Lifetime anxiety disorders
Any anxiety disorder (n=6132) 1.4 (1.1–1.8)** 1.1 (0.9–1.4) 1.9 (1.2–3.0)** 1.3 (0.8–1.9)
Panic disorder (n=1790) 1.7 (1.2–2.5)** 1.3 (0.9–1.9) 3.4 (1.9–6.1)*** 2.3 (1.3–4.2)**
Social anxiety disorder (n=1721) 1.5 (1.0–2.1)* 1.1 (0.8–1.6) 2.2 (1.2–4.2)* 1.4 (0.8–2.7)
Specific phobia (n=3407) 1.4 (1.0–1.8)* 1.1 (0.8–1.5) 1.4 (0.8–2.5) 0.9 (0.5–1.7)
Generalized anxiety disorder (n=1493) 2.1 (1.5–2.9)*** 1.6 (1.1–2.2)** 3.0 (1.6–5.6)** 1.9 (1.0–3.6)
NESARC, National Epidemiologic Study on Alcohol and Related Conditions ; OR, odds ratio ; CI, confidence interval.
a Analyses conducted among those with no history of non-medical prescription opioid use at wave 1.
b Analyses conducted among those with no history of abuse or dependence secondary to non-medical prescription opioid use at wave 1.
c Reference is absence of specific mood/anxiety disorder.
d Adjusted for baseline demographics (sex, age, race, and baseline family income, marital status, and employment status).
e Adjusted for baseline demographics and other baseline lifetime mood/anxiety disorders, other substance use (prescription opioid use model)/substance-use disorders (prescription
opioid disorder model).










1.1–2.1] were associated with incident non-medical
prescription opioid use at follow-up.
Non-medical opioid disorder due to non-medical use
Adjusted for demographics, almost all (any and
specific) baseline lifetime mood disorders and anxiety
disorders were associated with incident opioid dis-
order due to non-medical prescription opioid use
at follow-up. In the models further adjusted for other
baseline mood/anxiety disorders, and baseline sub-
stance use, associations were attenuated but baseline
lifetime any mood disorder (aOR 2.1, 95% CI 1.5–3.0),
MDD (aOR 1.7, 95% CI 1.2–2.5), dysthymia (aOR 2.2,
95% CI 1.1–4.2) and panic disorder (aOR 2.3, 95% CI
1.3–4.2) remained associated with incident opioid dis-
order due to non-medical prescription opioid use at
follow-up.
Discussion
We find evidence that supports all three postulated
causal models linking mood/anxiety disorders and
non-medical opioid use and disorder due to use and
the use of incident data provides more assurance of
the correct temporal sequencing. This study builds
upon our prior cross-sectional study (Martins et al.
2009a) as well as on the study of Schepis & Hakes
(2011) and provides further support for a strong
relationship between mood/anxiety disorders and
non-medical opioid use and disorder due to use.
Previously, using survival analyses techniques with
wave 1 data only we also found support for all three
models ; however, in that paper we only explored the
associations of mood/anxiety disorders with non-
medical use and dependence due to use (Martins et al.
2009a). By focusing on incident cases, evidence for
a precipitational model pathway was found, as
non-medical opioid use (but not disorder due to use)
predicted mood/anxiety disorders, especially for
respondents with non-medical use preceding any
anxiety disorder, since in the other direction the
association was non-significant. Previously, when
analysing wave 1 data only, we also found evidence
for a strong association between dependence due to
use and subsequent GAD and bipolar I disorder,
findings that were not corroborated in these incident
analyses with disorder (abuse/dependence) (Martins
et al. 2009a). By focusing on incident cases, evidence
for a self-medication pathway was also found, as
mood/anxiety disorders predicted incident non-
medical opioid use and disorder, particularly for re-
spondents with mood disorders such as dysthymia
and bipolar I disorder preceding non-medical use, and
any mood disorders, MDD, dysthymia and panic dis-
order predicting opioid disorder due to use, since in
the other direction associations were non-significant.
The previous study using only wave 1 data found
evidence for a strong self-medication pathway be-
tween pre-existing bipolar I disorder and GAD and
non-medical opioid dependence due to use (Martins
et al. 2009a). Finally, the presence of a general shared
vulnerability to both mood/anxiety disorders and
non-medical prescription opioid use cannot be ruled
out, since in several cases the magnitude of the associ-
ations had similar strength in both directions – from
non-medical use/disorder due to use to mood/anxiety
disorders and vice versa, a finding also found pre-
viously in the wave 1 data (Martins et al. 2009a).
The risk of incident anxiety disorders was increased
among respondents with baseline non-medical opioid
use after controlling for all covariates, providing sup-
port for a precipitational model in these cases. This is
consistent with findings from the study of Schepis &
Hakes (2011) that shows that the risk of incident
anxiety disorders was increased among respondents
with baseline non-medical opioid use without prior
psychopathology. It should be noted that the increased
risk for incident anxiety disorders was of similar mag-
nitude for non-medical users and heavy non-medical
users (sensitivity analyses, available upon request).
Thus, using opioids (or even withdrawal from
opioids) might precipitate anxiety disorders. This
suggests that there is a subgroup of people particu-
larly vulnerable to the future development of anxiety
disorders, and so individuals using prescription
opioids need to be closely monitored not only for the
possibility of engaging in non-medical use, but also for
the development of co-morbid psychiatric disorders.
Increased risk of incident opioid disorder due to non-
medical use occurred among respondents with base-
line mood disorders, MDD, dysthymia and panic
disorder, reinforcing the finding that respondents with
mood disorders might use opioids non-medically
to alleviate their mood symptoms. This again is con-
sistent with findings from cross-sectional studies
(Sullivan et al. 2005; Huang et al. 2006 ; Becker et al.
2008 ; Tetrault et al. 2008 ; Grella et al. 2009) and
builds upon our previous study (Martins et al. 2009a)
which provides support for a self-medication pathway
between opioid disorder andmood/anxiety disorders.
This is also consistent with findings from Robinson
et al. (2011) who show that self-medication in
anxiety disorders confers substantial risk of incident
substance-use disorders, however, in that study, the
authors did not test for associations of baseline anxiety
disorders specifically with incident prescription
opioid disorder, nor adjusted for baseline other sub-
stance use. Thus, early identification and treatment of
mood and anxiety disorders might reduce the risk for
self-medication with prescription opioids and the risk
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of future development of an opioid disorder. Fur-
thermore, an underlying shared vulnerability for non-
medical prescription opioid use and mood/anxiety
disorders could exist. Thus, family and twin studies
are needed to disentangle the relationship between
non-medical prescription opioid use/prescription
opioid disorder with mood/anxiety disorders, since
they could co-occur due to shared genetic or environ-
mental risk factors, similar to what was found when
examining the association between nicotine depen-
dence and major depression (Martins et al. 2009a). It is
important to bear in mind that as with other drug-use
disorders, opioid disorder due to non-medical use is a
genetically and phenotypically complex disorder
(Compton et al. 2005b). Moreover, the social environ-
ment in which population groups grow up certainly
plays a role in the underlying general vulnerability for
non-medical prescription opioid use/opioid disorder
and mood/anxiety disorders ; for example, McCabe
et al. (2007) have shown that, among college students,
most of them use prescription opioids non-medically
to self-medicate, followed by a smaller proportion that
use them to ‘get high’ or to experiment with these
drugs. In addition, studies have shown that the lead-
ing sources for obtaining prescription opioids for non-
medical use are family and friends (McCabe et al. 2007 ;
Martins et al. 2009b).
Several study limitations merit mention. First, loss
to follow-up might have introduced bias in the sample
and, consequently, in the generalization of results.
Furthermore, all information is based on self-report, as
in all large-scale epidemiologic surveys. As such, the
validity of these results is predicated on the accuracy
of the information provided by respondents. How-
ever, studies have shown that the AUDADIS-IV has
good reliability and validity (Grant et al. 2003, 2005).
The follow-up period between waves 1 and 2 of the
NESARC is only approximately 3 years, and does not
include any new cases that could occur in future years.
Thus, the results of our study may underestimate
the true magnitude of the associations between non-
medical opioid use and incidence of psychiatric dis-
orders. In addition, as acknowledged earlier, wave 2
of the NESARC combines prescription opioids with
Cox-2 inhibitors (which have no abuse potential) in a
single question about the non-medical use of pre-
scription pain medications, which could have some-
what inflated the incidence rate of prescription opioid
use (but not disorder) in our study (Boyd & McCabe,
2009). However, the incidence of non-medical pre-
scription opioid use in wave 2 of the NESARC is
similar to rates obtained with data from the 2004
(2.9%) and 2005 (2.6%) National Surveys of Drug Use
and Health (using recent-onset use as a proxy of inci-
dence ; SAMHSA, 2005, 2006) that asked specifically
about non-medical prescription opioid use. In ad-
dition, the sensitivity analyses we conducted suggest
that the incidence of non-medical prescription opioid
use in wave 2 is not over-inflated. Further, we do not
have information on whether non-medical opioid
users initiate opioid use seeking euphoria (via medical
prescription or not) or analgesia (via medical pre-
scription or not) and where the first significant ex-
posure occurred. Subtypes of opioid users may be
unique in many aspects of co-morbidity and demo-
graphics. Future research specifically focusing on
prescription opioid use and disorders may be able to
provide more information on subtypes of opioid users
in the general population. Another major limitation
of the study seems to be the use of lifetime use and
lifetime diagnosis at baseline, however, when we
attempted to run similar models with past-year use
diagnosis at baseline, the sample sizes were largely
reduced and we did not have power to run the
models. Last, to reduce the overall complexity, our
results are based on a set of statistical models that
only included a narrow set of covariates. Our models
were not adjusted for the 10 personality disorders
available in the NESARC dataset (Grant et al. 2004a).
However, estimates frommodels that also adjusted for
pain, family history and antisocial personality dis-
order were similar to the ones reported (data not
shown, available upon request).
Despite limitations, the present study adds sub-
stantial information to the literature on non-medical
prescription opioid use and prescription opioid dis-
order and psychopathology. Major strengths of the
data include how the NESARC project was adminis-
tered (national sampling frame and standardized
questions) and the longitudinal character of the data
(Grant et al. 1995, 2003). The large sample size of the
NESARC allows for statistical power to detect evi-
dence for the hypothesized pathways of not only non-
medical opioid use but also the less common condition
of opioid disorder that had resulted from non-medical
prescription opioid use with psychiatric disorders.
Further, the AUDADIS-IV has documented reliability
and validity in assessing drug-use disorders as well as
psychiatric disorders.
In conclusion, this study provides support for a bi-
directional pathway (self-medication and precipi-
tational) between non-medical prescription opioid
use/opioid disorder due to non-medical use and sev-
eral mood/anxiety disorders. In addition, it does
not rule out the existence of an underlying general
vulnerability that could explain these associations. It
is important for clinicians to investigate substance-
induced mood/anxiety disorders when treating
patients who use prescription opioids non-medically
or have a prescription opioid disorder as well as to ask
1270 S. S. Martins et al.
patients with mood/anxiety disorders about their
drug-using behavior.
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